Clinical Trial Update: MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase III trial evaluating MK-0431/ONO-5435 as a rapid-acting insulin secretagogue add-on therapy for Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MK-0431/ONO-5435

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED